EVALUATE STABILITY IN HOT, HUMID ENVIRONMENTS? HOW DO YOU KNOW RAW MATERIALS ARE PURE? HOW DO YOU KNOW IDENTIFY UNKNOWN METABOLITES? HOW DO YOU OPTIMIZE AN ANALYTICAL METHOD UNDER GMP? HOW DO YOU RE-OPTIM IANGES? HOW DO YOU DETECT POST-TRANSLATIONAL MODIFICATIONS? HOW DO YOU MONITOR CHARGE VARIANTS AND DE 32/233>? HOW DO YOU KNOW WHEN TO CONDUCT E/L STUDIES? HOW DO YOU FULLY CHARACTERIZE AN ANTIBODY DRUG IANTS AND DEGRADATIONS? HOW DO YOU MAKE BETTER DEVELOPMENT DECISIONS FASTER? HOW DO YOU RE-OPTIMIZE AN HOW DO YOU IDENTIFY UNKNOWN METABOLITES? HOW DO YOU OPTIMIZE AN ANALYTICAL METHOD UNDER GMP? HOW DO YOU W DO YOU IDENTIFY UNKNOWN METABOLITES? HOW DO YOU EVALUATE PRODUCT PACKAGING? HOW DO YOU IDENTIFY THE /HAT ANALYTICAL TECHNIQUE TO USE? HOW DO YOU SIMULTANEOUSLY TEST FOR TWO BYPRODUCTS? HOW DO YOU CHARA /ABILITY IN HOT, HUMID ENVIRONMENTS? HOW DO YOU KNOW RAW MATERIALS ARE PURE? HOW DO YOU CHARA /ABILITY IN HOT, HUMID ENVIRONMENTS? HOW DO YOU KNOW RAW MATERIALS ARE PURE? HOW DO YOU CHARA /ABILITY IN HOT, HUMID ENVIRONMENTS? HOW DO YOU KNOW RAW MATERIALS ARE PURE? HOW DO YOU KNOW IF A BIOSIM KNOWN METABOLITES? HOW DO YOU OPTIMIZE AN ANALYTICAL METHOD UNDER GMP? HOW DO YOU KNOW IF A BIOSIM

APPLICATION NOTE

Development and Validation of an MRM Assay for the Determination of Residual Tetracycline in a Protein Drug Substance and Process Intermediate

R. Tobias¹, C. Detchou¹, J. Tompkins¹, J. Anders¹, S. Rovetta², P. Belloni², G-P. Rizzardi², and J. McEntire² (1) EAG Laboratories (2) MolMed S.p.A

ABSTRACT

Purpose: A UPLC-MRM-MS Assay was developed and validated to quantitate the residual Tetracycline inNGR-hTNF Drug Substance and Process Intermediates.

Methods: A Tetracycline Standard and pipemidic acid used as the Internal Standard were spiked intoNGR-hTNF Drug Substance and In-Process Intermediate Buffer containing 20 mM HEPES, 0.1 M NaCl, and 8M urea, pH 7. The samples were chromatographed on a Zorbax 300SB-C8 (4.6 x 50 mm, 3.5 μ m) and eluted on an acetonitrile gradient in 0.1% formic acid. An MRM-MS Assay was developed on a Waters UPLC and AB Sciex 4000 QTRAP LC/MS/MS for both Drug Substance and Process Intermediates of NGR-hTNF.

Results: An MRM-MS Assay for quantitation of residual Tetracycline in both NGR-hTNF Drug Substance and In-Process Intermediate Buffer was developed and validated. The Tetracycline in these samples was analyzed directly in the Assay without prior clean-up of the protein sample. Linearity (r = 0.998 and 0.994 for Drug Substance and Process Buffer, respectively) of the Assay was demonstrated in this study. Accuracy by recovery of Tetracycline ranged from 109 to 114% in the Drug Substance, and 97 to 109% in the Process Buffer. The Intra Day and Intermediate Precisions were within 10%, and 15%, respectively in either matrix. The LOQ of the Assay was 0.8 ng/mL and 0.6 ng/mL of Tetracycline in the Drug Substance and Process Buffer, respectively. For Assay Specificity, the various buffers tested in this study did not interfere with the quantitation of Tetracycline. Small purposeful changes in gradient slope, column temperature, and formic acid in the mobile phase in the Assay resulted in less than 5% change in the concentration of Tetracycline indicating the method is robust.

Conclusions: A UPLC-MRM Assay was developed and validated for the determination of residual tetracycline in NGRhTNF Drug Substance and Process Intermediate. The method determines the concentration of Tetracycline directly in protein samples without prior protein clean-up or precipitation.

BACKGROUND

MRM-based Assay has been a reliable standard test to quantitate small molecule Drug Substance in pharmacokinetic and clinical samples due to its exceptional sensitivity and specicity. Recently, the MRM platform method has been gaining much attention in supporting drug development in large molecule therapeutics and biologics. In the present study, Tetracycline, which is commonly used in the manufacture of geneticallyexpressed proteins, was quantified in the presence of the protein Drug Substance and Process Intermediates by MRM MS. The samples were directly analyzed without prior clean-up of the protein and bioprocessing components.

OBJECTIVE

The objective of the current study is to develop and validate a UPLC-MRM-MS Assay to quantitate the residual Tetracycline in NGR-hTNF Drug Substance and Process Intermediates.

METHODS

Materials

The main materials used in this project consist of a genetically expressed recombinant protein of NGR-hTNF and commerciallyavailable Tetracycline and Pipemidic Acid Standards. The materials included puried Drug Substance in a drug formulation.

Equipment

The primary equipment used in this project included a Waters Acquity Binary UPLC and Sciex ABI 4000 QTRAP MS/MS system.

Sample Preparation

The general procedure consisted of spiking Tetracycline and Pipemidic Acid (Internal Standard) Standards into either the protein Drug Substance or In-Process Intermediate Buer. Following the preparation, the samples are directly analyzed by UPLC-MRM MS.

UPLC Conditions

The sample was chromatographed onto a Zorbax 300SB-C8 4.6 x 50 mm, 3.5 μ m at 40°C. The analyte is eluted in an acetonitrile gradient containing 0.1% formic acid at 0.5 ml/min.

APPLICATION NOTE

Development and Validation of an MRM Assay for the Determination of Residual Tetracycline in a Protein Drug Substance and Process Intermediate

QTRAP Parameters

Analysis was performed on MRM mode and positive ion detection using a Sciex ABI 4000 QTRAP MS/MS system. The transition ion pairs used were as follows:

	Precursor ion (m/z)	Product ion (m/z)	Dwell time (msec)
Tetracycline	445	410	200
Pipemidic Acid	304	286	200

RESULTS

Figure 1. (below, left) Tetracycline Linearity Plot in Drug Substance Figure 2. (below, right) Tetracycline Linearity Plot in Process Buffer




Figure 3. (below) Representative Chromatograms for Specificity: Drug Substance and Process Buffer




Figure 4. (below) Representative Chromatograms for Specificity: Citrate Buffer and CMS




Figure 5. (below) Representative Chromatograms for Solution Stability: Freeze-Thaw




Figure 6. (below) Representative Chromatograms for Robustness: Gradient Slope




Figure 7. (below) Representative Chromatograms for Robustness: Column Temperature

Sampo Nerve "BEIR J MPAJ" Saman D. Pesk Name "445.2 (415.3" Shee(ee) "445.5	File 'F 6428200	The DATE		Sample Name "WIRC J. 597A2" Sample ID " File '7 6080213A13 wff Peak Name "2013/2563" Manajes '704.0288.0 am/	
Commune - Annotation -		1.0		Comment - Avedage - Englise Tolers 1 Englise Type (TARNer) 844	
opentration: 5/6 Louisted Comix 0.000 su/ml	Sans.	2.52			
q. late: 6/26/2013 q. Time: 10119181 PM	100		Nominal	Ang. Inter 1, 200 March 1, 200	
dified: So			romman		
	2140			Proc. Algorithm: Intelligum - 12A I	
a. Deak BalghAi 500.00 cps a. Deak Midshs 0.00 sec	*1245			Min. Junk Meight: 100.00 Spn Min. Junk Midthn 0.00 and 5604	
withing Widths 0 points	+104			Secondary Hiddan 0 points 6 97 Hindbert 30.6 Red Sabet-	
a Balating BTy 55	et find			The black pri the training the	
A. Trees Valley	6 Ged			Tat. Two: Valley	
itantian Tinas 7.18 sin				Battenian Finer 6.41 min Areas 102/100 counts 2504	
	4.0+4			Ralphi 8.04a+004 spa	
d Times 5,52 sto.	2.044	1.0		Start Tome: 6.39 min. 1564	
	0.0				24 2
Sample Name: "BINIC 2 SSFAZ Lo. Co. P. 1			0 12 14 16 18 20 22 Tens, min	2 8 8 2 4 6 8 10 2 19 19 10 20 20 20 20 10 10 10 10 10 20 20 20 10 10 10 10 10 10 10 10 10 10 10 10 10	24 3
Pask Name "445.3 / 410.3" Manjen "445.0 Comment " Anotation "	William/	CADDONDALL WIT		Server Name (MH20 2, 2014) Co. (C.) " Server 0." Yes 1 602020540 APP Prex Name (2012) 286 // Mancion (2012) 004.0288.0 am/ Domant " Accelera "	
				Earpie Index: 1	
apis Dypes Unknown acceptention: Sik		7,25		fample Types Balances B/S Types	
Iculated Conce 0.000 sprat	"and-		-5%		
Times Meridan's PR	180		370		
Lifed: Bo	21.64			Notified: No g20e4-	
in. Peak Widths 0.00 sec	1245			No. Push Middan 0.00 neg 6204	
Windowi 20.0 sec	2104			27 Windows 20.0 840 \$1044	
e Belative BTy Bp	50.041			The Belative PTy No. 2004	
the Types Valley sin	6.0x4			Int. Types Valley Parameters Pines 6.46 min \$1004	
	4.044				
art Times 0.978+000 cps	2.04				
d Times 7.66 min		651		End line: 6.84 min 1204-	
	0.0	2 4 8 8 9	0 12 14 19 19 20 22		24 2
Sample Name 199180 2 30FA214 Car In 18 Past Name 1995 2 (1992) Standard 1995 0	angle (2." File 7	OK282012A/7 with		Sampia Name, "BEND 2, SERVICE, Co. 1", Sampia Co.", File, Y GEDETEN/Twitt Prod. Name, "2016 (1281)", Massimi, "2016/2016 Came"	
Comment " Amounter."				Comment: A scrabin we water and a scrabin and ascrabin and a scrabin and ascrabin and a scrabin and ascrabin and a scrabin and a scrabin and a scrabin and a	
spie Pype: Unknown	*2.041	2.15		Sarple Type: Inknown Forwarding N/A # 1	
			+5%		
4/28/2013 5. Time: 6/28/2013	+1.845		+370	Are. Trace 4 (20/2012 Are Area	
in the second second	244			Aller Aller	
nr. Algorithms Istalliguan - 124	-1.44			Proc. Algorithm: Intelliguan - 12A TP.004	
othing Widths 0.00 sec	124			His, Yeak Middah 0.00 qa His, Yeak Middah 0.00 sed Southing Within 0.	
	2104				
s Belative BTy 50	Stat			Experies 22: 6.02 min. Capot	
- Trans Tailor	104			int. Tunn: Valler	
testics final 7.11 sin.				Padation Fine: 6.34 min	
cabts 2.01++000 cpm art Timer 6.85 min.	4.044			Bought 9,724-004 opn 2,004	
Tibes 7.50 pin	2.04	6.20		End Time: 4.42 min 1884	
	0.0	1 4 4 4 4		10 10 10 10 10 10 10 10 10 10 10 10 10 1	P 1
			Tree min	and a set of the set o	

APPLICATION NOTE

Development and Validation of an MRM Assay for the Determination of Residual Tetracycline in a Protein Drug Substance and Process Intermediate

Table 1. (below) Summary of Results: Linearity, Accuracy, and Repeatability

Test	Acceptance Criteria	Results			
Linearity	Correlation Coefficient must	Sample Drug Substance		Correlation Coefficient (r) 1.00	
	be $r \ge 0.98$				
		Process Buffer		1.00	
		Sample	Level	%Recovery	Mean %Recovery
		Drug Substance	30 ng/mL	111	109
				109	
				108	
			50 ng/mL	104	108
				109	
				111	
	Recovery for the DS and the		75 ng/mL	126	114
	30 ng/mL spiked			109	
	representative Process Intermediate samples must be between 75 to 125% of the theoretical value • Recovery for the 10 ng/mL Process Intermediate samples will be reported only			105	
			30 ng/mL	112	109
Accuracy by Recovery		Process Buffer		108	
				107	
			50 ng/mL	103	103
				112	
				94	
			75 ng/mL	95	97
				99	
				97	
		Process termediate	10 ng/mL		100
		Process Intermediate	30 ng/mL		100
Repeatability	• %RSD ≤ 10% of the determinations	%RSD = 2			

Table 2. (above) Summary of Results: LOQ Determination,Solution Stability, and Robustness

LOQ Determination	• Concentration obtained from the calculation,	Component	Concentration (ng/mL)	%RSD
	$LOQ = 10\left(\frac{SD}{S}\right)$	Drug Substance	0.76	
	 will be reported. Concentration and %RSD 	Process Buffer	0.56	
	obtained with the LOQ- spiked samples will be reported	LOQ Confirmation	0.9	5
	-	Time Point	Condition	%RD
Solution Stability	• Change of results $\geq 20\%$ RD		Freeze/Thaw	
	vs. Time 0 (or initial time) indicates the samples are not	Initial	Refrigerated	
	stableReport all results and	24 Hour	Freeze/Thaw	-7
		24 Hour	Refrigerated	-12
	provide representative chromatograms	48 Hour	Freeze/Thaw	-14
	5	48 Hour	Refrigerated	-16
		Parameter	Change	% RD
Robustness	• Change of results $\geq 20\%$ RD	Nominal	NA	NA
	vs. nominal conditions	Gradient slope	-5%	-2
	indicates a critical method parameter	Gradient slope	+5%	-3
	 Report all results and 	Column	-5%	-4
	provide representative	temperature	+5%	-1
	chromatograms	Formic acid	-5%	0
		concentration	+5%	1

DISCUSSIONS

An MRM-MS Assay was validated to quantitate residual Tetracycline in both NGR-hTNF Drug Substance and in Process Intermediate Buffer. Linearity was demonstrated from 1 ng/mL to 75 ng/mL for both sample matrices. In addition to spiked Drug Substance and Process Intermediate Buffer, Accuracy of the Tetracycline determination was also confirmed in actual Process Intermediate Sample spiked with the Tetracycline Standard. The LOQ of the Assay was 0.8 ng/mL for the Drug Substance and 0.6 ng/mL for the Process Intermediate Buffer.

For Specificity, the various buffer and protein samples tested in this study did not interfere with the quantitation of Tetracycline in these samples. The planned changes in gradient slope, column temperature, and Formic Acid in the Mobile Phase in the Assay resulted in less than 5% change in Tetracycline concentration. Hence, none of these Assay parameters were considered critical elements of the assay for quantitation of Tetracycline.

In conclusion, the results obtained from this study met the acceptance criteria for the evaluation of System Suitability, Accuracy by Recovery, Repeatability, Intermediate Precision, Specificity, LOD Determination, LOQ Determination, Solution Stability, and Robustness. The totality of the validation study included determination of Tetracycline in test materials containing various levels of protein concentrations. Furthermore, the Process Intermediate Buffer used in this study is a representative of the Process Intermediates typically encountered in the manufacture of the NGR-hTNF Drug Substance.

CONCLUSION

A UPLC-MRM Assay was developed and validated for the determination of residual Tetracycline in protein Drug Substance and Process Intermediates. The method passed all validation criteria and is deemed validated and suitable for its intended use.

